25 min listen
David Donabedian, CEO and co-founder of Axial Biotherapeutics
David Donabedian, CEO and co-founder of Axial Biotherapeutics
ratings:
Length:
24 minutes
Released:
Apr 23, 2018
Format:
Podcast episode
Description
Axial biotherapeutics is a biopharmaceutical company developing new therapeutics to treat diseases of the central nervous system. According to Dr. David Donabedian, CEO, and co-founder, researchers hope to leverage the link between the human gut microbiome and central nervous system including Autism and Parkinson’s Disease. While there are many factors that have contributed to an increase in the number of children with symptoms of autism, Dr. Donabedian suggests that environmental factors may have caused changes in the diversity of bacteria that children are exposed to. Therefore, Axial has taken a unique approach by focusing on the gut-brain axis. Initial testing at Axial has shown that gut-selective therapies have resulted in improvements in core behaviors and symptoms associated with autism as well as reducing symptoms due to gastrointestinal disorders.
Released:
Apr 23, 2018
Format:
Podcast episode
Titles in the series (100)
Using Artificial Intelligence In Judicial Decision-making | Interview With Dr. Dimitrios Tsarapatsanis.: This week I interviewed Dr. Dimitrios Tsarapatsanis who has helped develop an artificially intelligent system that can predict the outcome of a case with a whopping 79% accuracy. Dr. Dimitrios explains… by Finding Genius Podcast